Online video improves clinical outcomes in adults with atopic dermatitis: A randomized controlled trial - 10/08/11
Abstract |
Background |
Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by intense pruritus that causes significant disease and psychosocial burden in patients. Patient education has the potential to improve clinical outcomes and patient knowledge of this condition.
Objectives |
We sought to assess the effectiveness of online video education at improving AD knowledge and disease severity compared with a written pamphlet, and to determine the usefulness and appeal of the two educational delivery vehicles.
Methods |
In a randomized controlled trial, 80 participants were randomized to receive either online video-based patient education or written pamphlet education about AD and its management. We assessed AD disease severity using the patient-oriented eczema measure (POEM) scale. AD knowledge was assessed with standardized questionnaires at baseline and after the 12-week intervention.
Results |
All participants had similar baseline knowledge and AD severity at the beginning of the study. On study completion, improvements in AD knowledge assessed by questionnaire were significantly greater in the video group than the pamphlet group (3.05 vs 1.85, P = .011). Online video-based education resulted in greater improvement in clinical outcome, as measured by POEM, compared with pamphlet-based education (POEM score reduction of 3.30 vs 1.03, P = .0043). Finally, although the usefulness of both interventions was rated equally (P = .77), the online video was significantly more appealing than the pamphlet (P = .0086).
Limitations |
This study is limited to AD in adults.
Conclusion |
Online video for patient education is an effective and appealing tool for improving clinical outcomes in adult patients with AD.
Le texte complet de cet article est disponible en PDF.Key words : atopic dermatitis, patient education, POEM, randomized controlled trial, video education
Plan
Funding sources: None. |
|
Dr Lio reports receiving consulting fees from 3M and has been an investigator for Promius Pharma and LEO Pharma within the past 5 years. Drs Armstrong, Kim, Idriss, and Larsen have no conflicts of interest to declare. |
|
Reprints not available from the authors. |
Vol 64 - N° 3
P. 502-507 - mars 2011 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?